9 May 2017
In the past 30 years, there have been substantive advances in Synthetic Biology and many of the processes have been significantly simplified. However, it has not seen wide uptake in normal laboratories.
This exciting conference brought together professionals from a range of industries who have commercially exploited this technology.
Available Conference Papers:
Biocatalytic retrosynthesis – designing new routes to target molecules,
Nick Turner, University of Manchester
Development of an efficient API manufacturing process: A marriage of chemistry and biocatalysis,
Pat O’Neill, Pfizer
Insights into pharmaceutical biocatalysis: discovery and process development,
Paul Devine, Merck
Chiral amine synthesis: Transaminases and beyond,
Ursula Schell, Johnson Matthey